Rapid Micro Biosystems (NASDAQ:RPID) Stock Rating Upgraded by Wall Street Zen

Rapid Micro Biosystems (NASDAQ:RPID) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Rapid Micro Biosystems presently has a consensus rating of “Hold” and an average price target of $8.00.

Rapid Micro Biosystems Stock Up 0.5%

Shares of NASDAQ:RPID opened at $2.13 on Friday. The stock has a market cap of $96.83 million, a price-to-earnings ratio of -1.99 and a beta of 1.59. The company has a quick ratio of 2.36, a current ratio of 3.31 and a debt-to-equity ratio of 0.57. Rapid Micro Biosystems has a 12-month low of $2.00 and a 12-month high of $4.94. The business’s 50 day moving average is $3.32 and its 200 day moving average is $3.47.

Rapid Micro Biosystems (NASDAQ:RPID) last announced its earnings results on Thursday, March 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.05). The company had revenue of $11.28 million for the quarter, compared to analysts’ expectations of $10.93 million. Rapid Micro Biosystems had a negative net margin of 140.30% and a negative return on equity of 95.40%. On average, sell-side analysts forecast that Rapid Micro Biosystems will post -1.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Rapid Micro Biosystems news, COO John J. Addington Wilson sold 9,603 shares of the business’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $4.32, for a total value of $41,484.96. Following the transaction, the chief operating officer owned 316,762 shares of the company’s stock, valued at approximately $1,368,411.84. The trade was a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Sean M. Wirtjes sold 17,254 shares of the business’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $3.92, for a total value of $67,635.68. Following the completion of the transaction, the chief financial officer directly owned 563,674 shares in the company, valued at approximately $2,209,602.08. This represents a 2.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 249,705 shares of company stock worth $1,021,364 in the last ninety days. Company insiders own 29.96% of the company’s stock.

Institutional Trading of Rapid Micro Biosystems

Several hedge funds have recently made changes to their positions in the company. Millennium Management LLC bought a new stake in shares of Rapid Micro Biosystems in the fourth quarter valued at $338,000. 683 Capital Management LLC bought a new stake in shares of Rapid Micro Biosystems in the fourth quarter valued at $350,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Rapid Micro Biosystems in the fourth quarter valued at $71,000. Fifth Lane Capital LP bought a new stake in shares of Rapid Micro Biosystems in the fourth quarter valued at $51,000. Finally, Barclays PLC bought a new stake in shares of Rapid Micro Biosystems in the fourth quarter valued at $72,000. 52.60% of the stock is currently owned by institutional investors.

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.